supply of des-abbreviated dapt long -coronary drug eluting stentsdes-abbreviated dapt long -coronary drug eluting stents,srphc153048-des-abbreviated dapt long -coronary drug eluting stents wit h (1) platinum chromium alloy (2) coating of bioabsorbable polymer carrier for active drug everolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm. the length of the stent should be from 12mm t o 48 mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system s hould be monorail (single operator exchange or rapid exchange). (6) stent should be c ompatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tende r bid. (9) the long term efficacy and safety of the stent the rates of in-stent restenosi s (isr) and in-situ thrombosis (ist) should be documented / published in peer reviewed sc ientific journals. (10) safety of abbreviated (three month) dual antiplatelet therapy fo r high bleeding risk patients should be documented in peer reviewed journals. (11) the manufacturer/supplier should submit proof of supply of the stent to a major governme nt institute. bis standards for the drug eluting stent are not available. (reference:bis catalogue ). unit:no [ warranty period: 30 months after the date of delivery ] ]